Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Pelaia, Girolamo ^a   Vatrella, Alessandro ^b   Busceti, Maria Teresa ^a   Gallelli, Luca ^a   Calabrese, Cecilia ^c   Terracciano, Rosa ^a   Maselli, Rosario ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CORTICOSTEROID; CYTOKINE; MEPOLIZUMAB; RESLIZUMAB;

ALLERGIC ASTHMA; ANTIGEN PRESENTATION; ASTHMA; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EOSINOPHIL; GAMMA DELTA T LYMPHOCYTE; GENE REARRANGEMENT; HUMAN; INFLAMMATORY CELL; LYMPHOCYTE DIFFERENTIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER T CELL; NEUTROPHIL; PATHOGEN LOAD; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT INFLAMMATION; REVIEW; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; TH2 CELL; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; EOSINOPHILIA; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE; PHENOTYPE;

ANIMALS; ASTHMA; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; EOSINOPHILIA; HUMANS; INFLAMMATION; LYMPHOCYTES; NEUTROPHILS; PHENOTYPE; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TH2 CELLS;

EID: 84927126791     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/879783     Document Type: Review

References (86)

1. G. P. Anderson, "Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease, " The Lancet, vol. 372, no. 9643, pp. 1107-1119, 2008.
2. S. T. Holgate, H. S. Arshad, G. C. Roberts, P. H. Howarth, P. Thurner, and D. E. Davies, "A new look at the pathogenesis of asthma, " Clinical Science, vol. 118, no. 7, pp. 439-450, 2010.
3. C. Anandan, U. Nurmatov, O.C. P. Van Schayck, and A. Sheikh, "Is the prevalence of asthma declining? Systematic review of epidemiological studies, " Allergy, vol. 65, no. 2, pp. 152-167, 2010.
4. M. Masoli, D. Fabian, S. Holt, and R. Beasley, "The global burden of asthma: executive summary of the GINA dissemination committee report, " Allergy, vol. 59, no. 5, pp. 469-478, 2004.
5. P. Chanez and M. Humbert, "Asthma: still a promising future?" European Respiratory Review, vol. 23, no. 134, pp. 405-407, 2014.
6. P. J. Barnes, "The cytokine network in asthma and chronic obstructive pulmonary disease, " Journal of Clinical Investigation, vol. 118, no. 11, pp. 3546-3556, 2008.
7. S. E. Wenzel, "Complex phenotypes in asthma: current definitions, " Pulmonary Pharmacology & Therapeutics, vol. 26, no. 6, pp. 710-715, 2013.
8. R. Pawankar, M. Hayashi, S. Yamanishi, and T. Igarashi, "The paradigm of cytokine networks in allergic airway inflammation, " Current Opinion in Allergy and Clinical Immunology, vol. 15, no. 1, pp. 41-48, 2015.
9. B. N. Lambrecht and H. Hammad, "The immunology of asthma, " Nature Immunology, vol. 16, no. 1, pp. 45-56, 2014.
10. G. G. Brusselle, T.Maes, and K. R. Bracke, "Eosinophilic airway inflammation in nonallergic asthma, " Nature Medicine, vol. 19, no. 8, pp. 977-979, 2013.
11. D. J. Erle and D. Sheppard, "The cell biology of asthma, " The Journal of Cell Biology, vol. 205, no. 5, pp. 621-631, 2014.
12. S.Yu, H. Y. Kim, Y.-J. Chang, R. H. Dekruyff, and D.T.Umetsu, "Innate lymphoid cells and asthma, " Journal of Allergy and Clinical Immunology, vol. 133, no. 4, pp. 943-950, 2014.
13. H17 cells in asthma and inflammation, " Biochimica et Biophysica Acta, vol. 1810, no. 11, pp. 1066- 1079, 2011.
14. H. E. Trejo Bittar, S. A. Yousem, and S. E.Wenzel, "Pathobiology of severe asthma, " Annual Review of Pathology, vol. 10, no. 1, pp. 511-545, 2015.
15. H. Vroman, B. van den Blink, and M. Kool, "Mode of dendritic cell activation: The decisive hand in Th2/Th17 cell differentiation. Implications in asthma severity?" Immunobiology, vol. 220, no. 2, pp. 254-261, 2015.
16. H. Hammad, M. Chieppa, F. Perros, M. A. Willart, R. N. Germain, and B. N. Lambrecht, "House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells, " Nature Medicine, vol. 15, no. 4, pp. 410-416, 2009.
17. P. G.Woodruff, B.Modrek, D. F. Choy et al., "T-helper type 2- driven inflammation defines major subphenotypes of asthma, " American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 5, pp. 388-395, 2009.
18. C. M. Lloyd, "Dust mites' dirty dealings in the lung, " Nature Medicine, vol. 15, no. 4, pp. 366-367, 2009.
19. Z. Su, J. Lin, F. Lu et al., "Potential autocrine regulation of interleukin-33/ST2 signaling of dendritic cells in allergic inflammation, " Mucosal Immunology, vol. 6, no. 5, pp. 921-930, 2013.
20. T. Kallinich, K. C. Beler, U.Wahn, P. Stock, and E. Hamelmann, "T-cell co-stimulatory molecules: Their role in allergic immune reactions, " European Respiratory Journal, vol. 29, no. 6, pp. 1246- 1255, 2007.
21. G. E. Kaiko, J. C. Horvat, K. W. Beagley, and P. M. Hansbro, "Immunological decision-making: how does the immune system decide to mount a helper T-cell response?" Immunology, vol. 123, no. 3, pp. 326-338, 2008.
22. M. Larché, D. S. Robinson, and A. B. Kay, "The role of T lymphocytes in the pathogenesis of asthma, " Journal of Allergy and Clinical Immunology, vol. 111, no. 3, pp. 450-463, 2003.
23. G. E. Kaiko and P. S. Foster, "New insights into the generation of Th2 immunity and potential therapeutic targets for the treatment of asthma, " Current Opinion in Allergy and Clinical Immunology, vol. 11, no. 1, pp. 39-45, 2011.
24. P. C. Fulkerson and M. E. Rothenberg, "Targeting eosinophils in allergy, inflammation and beyond, " Nature Reviews Drug Discovery, vol. 12, no. 2, pp. 117-129, 2013.
25. Y. M. Park and B. S. Bochner, "Eosinophil survival and apoptosis in health and disease, " Allergy, Asthma and Immunology Research, vol. 2, no. 2, pp. 87-101, 2010.
26. J. M. Felton, C. D. Lucas, A. G. Rossi, and I. Dransfield, "Eosinophils in the lung-modulating apoptosis and efferocytosis in airway inflammation, " Frontiers in Immunology, vol. 5, article 302, 2014.
27. C. Bandeira-Melo, P. T. Bozza, and P. F. Weller, "The cellular biology of eosinophil eicosanoid formation and function, " Journal of Allergy and Clinical Immunology, vol. 109, no. 3, pp. 393-400, 2002.
28. M. Peters-Golden and W. R. Henderson Jr., "Mechanisms of disease: Leukotrienes, " The New England Journal of Medicine, vol. 357, no. 18, pp. 1841-1854, 2007.
29. T. S. Hallstrand and W. R. Henderson, "An update on the role of leukotrienes in asthma, " Current Opinion in Allergy and Clinical Immunology, vol. 10, no. 1, pp. 60-66, 2010.
30. S. Hall and D. K. Agrawal, "Keymediators in the immunopathogenesis of allergic asthma, " International Immunopharmacology, vol. 23, no. 1, pp. 316-329, 2014.
31. A. A. Humbles, C. M. Lloyd, S. J. McMillan et al., "A critical role for eosinophils in allergic airways remodeling, " Science, vol. 305, no. 5691, pp. 1776-1779, 2004.
32. E. A. Jacobsen, R. A. Helmers, J. J. Lee, and N. A. Lee, "The expanding role(s) of eosinophils in health and disease, " Blood, vol. 120, no. 19, pp. 3882-3890, 2012.
33. J. A. Walker, J. L. Barlow, and A. N. J. McKenzie, "Innate lymphoid cells-how did we miss them?" Nature Reviews Immunology, vol. 13, no. 2, pp. 75-87, 2013.
34. A. N. McKenzie, H. Spits, and G. Eberl, "Innate lymphoid cells in inflammation and immunity, " Immunity, vol. 41, no. 3, pp. 366-374, 2014.
35. L. Xue, M. Salimi, I. Panse et al., "Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologousmolecule expressed on Tα2 cells, " Journal of Allergy and Clinical Immunology, vol. 133, no. 4, pp. 11847- 11947, 2014.
36. J. M. Mjösberg, S. Trifari, N. K. Crellin et al., "Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161, " Nature Immunology, vol. 12, no. 11, pp. 1055-1062, 2011.
37. K.R. Bartemes, G.M. Kephart, S. J. Fox, and H. Kita, "Enhanced innate type 2 immune response in peripheral blood from patients with asthma, " The Journal of Allergy and Clinical Immunology, vol. 134, no. 3, pp. 6714-6784, 2014.
38. Y.-J. Chang, H. Y. Kim, L. A. Albacker et al., "Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity, " Nature Immunology, vol. 12, no. 7, pp. 631-638, 2011.
39. K. R. Bartemes, K. Iijima, T. Kobayashi, G. M. Kephart, A. N. McKenzie, and H. Kita, "IL-33-responsive lineage-CD25+CD44hα lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs, " Journal of Immunology, vol. 188, no. 3, pp. 1503-1513, 2012.
40. B. D. Levy, G. T. de Sanctis, P. R. Devchand et al., "Multipronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4, " Nature Medicine, vol. 8, no. 9, pp. 1018- 1023, 2002.
41. P. Ilmarinen and H. Kankaanranta, "Eosinophil apoptosis as a therapeutic target in allergic asthma, " Basic & Clinical Pharmacology & Toxicology, vol. 114, no. 1, pp. 109-117, 2014.
42. X. Zhang, E. Moilanen, and H. Kankaanranta, "Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone, " European Journal of Pharmacology, vol. 406, no. 3, pp. 325-332, 2000.
43. X. Zhang, E. Moilanen, I. M. Adcock, M. A. Lindsay, and H. Kankaanranta, "Divergent effect of mometasone on human eosinophil and neutrophil apoptosis, " Life Sciences, vol. 71, no. 13, pp. 1523-1534, 2002.
44. N. A. Molfino, D. Gossage, R. Kolbeck, J. M. Parker, and G. P. Geba, "Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor, " Clinical & Experimental Allergy, vol. 42, no. 5, pp. 712-737, 2012.
45. G. Pelaia, A. Vatrella, and R. Maselli, "The potential of biologics for the treatment of asthma, " Nature Reviews Drug Discovery, vol. 11, no. 12, pp. 958-972, 2012.
46. L. Gallelli, M. T. Busceti, A. Vatrella, R. Maselli, and G. Pelaia, "Update on anti-cytokine treatment for asthma, " BioMed Research International, vol. 2013, Article ID 104315, 10 pages, 2013.
47. P. Haldar, C. E. Brightling, B. Hargadon et al., "Mepolizumab and exacerbations of refractory eosinophilic asthma, " The New England Journal of Medicine, vol. 360, no. 10, pp. 973-984, 2009.
48. P. Nair, M.M.M. Pizzichini, M. Kjarsgaard et al., "Mepolizumab for prednisone-dependent asthma with sputum eosinophilia, " The New England Journal of Medicine, vol. 360, no. 10, pp. 985- 993, 2009.
49. I.D. Pavord, S. Korn, P. Howarth et al., "Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial, "The Lancet, vol. 380, no. 9842, pp. 651- 659, 2012.
50. H. G. Ortega, M. C. Liu, I. D. Pavord et al., "Mepolizumab treatment in patients with severe eosinophilic asthma, " The New England Journal of Medicine, vol. 371, no. 13, pp. 1198-1207, 2014.
51. M. Castro, S. Mathur, F. Hargreave et al., "Reslizumab for poorly controlled, eosinophilic asthma: A randomized, placebocontrolled study, " American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 10, pp. 1125-1132, 2011.
52. W. W. Busse, R. Katial, D. Gossage et al., "Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti- IL-5 receptor α antibody, in a phase I study of subjects with mild asthma, " Journal of Allergy and Clinical Immunology, vol. 125, no. 6, pp. 1237-1244, 2010.
53. M. Castro, S. E. Wenzel, E. R. Bleecker et al., "Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: A phase 2b randomised dose-ranging study, "The Lancet Respiratory Medicine, vol. 2, no. 11, pp. 879-890, 2014.
54. D. C. Newcomb and R. S. Peebles, "Th17-mediated inflammation in asthma, " Current Opinion in Immunology, vol. 25, no. 6, pp. 755-760, 2013.
55. L. Cosmi, F. Liotta, E. Maggi, S. Romagnani, and F. Annunziato, "Th17 cells: new players in asthma pathogenesis, " Allergy, vol. 66, no. 8, pp. 989-998, 2011.
56. H17-associated cytokines (IL-17A and IL-17F) in severe asthma, " Journal of Allergy and Clinical Immunology, vol. 123, no. 5, pp. 1185-1187, 2009.
57. + T cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 3, pp. 876-881, 2009.
58. H17 cell differentiation by innate immune signals, " Cellular &Molecular Immunology, vol. 9, no. 4, pp. 287-295, 2012.
59. H17 and regulatory T cells, " Nature, vol. 441, no. 7090, pp. 235-238, 2006.
60. M. J. McGeachy, Y. Chen, C. M. Tato et al., "The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo, " Nature Immunology, vol. 10, no. 3, pp. 314-324, 2009.
61. N. C. Thomson, R. Chaudhuri, and E. Livingston, "Asthma and cigarette smoking, " European Respiratory Journal, vol. 24, no. 5, pp. 822-833, 2004.
62. R. Polosa and N. C.Thomson, "Smoking and asthma: dangerous liaisons, " European Respiratory Journal, vol. 41, no. 3, pp. 716- 725, 2013.
63. G. G. Brusselle, S. Provoost, K. R. Bracke, A. Kuchmiy, and M. Lamkanfi, "Inflammasomes in respiratory disease: From bench to bedside, " Chest, vol. 145, no. 5, pp. 1121-1133, 2014.
64. T.-H. Lee, H. J. Song, and C.-S. Park, "Role of inflammasome activation in development and exacerbation of asthma, " Asia Pacific Allergy, vol. 4, no. 4, pp. 187-196, 2014.
65. F. Ozseker, S. Buyukozturk, B. Depboylu et al., "Serum amyloid A (SAA) in induced sputum of asthmatics: A new look to an old marker, " International Immunopharmacology, vol. 6, no. 10, pp. 1569-1576, 2006.
66. N. Säid-Sadier and D. M. Ojcius, "Alarmins, inflammasomes and immunity, " Biomedical Journal, vol. 35, no. 6, pp. 437-449, 2012.
67. J. L. Simpson, S. Phipps, K. J. Baines, K. M. Oreo, L. Gunawardhana, and P. G. Gibson, "Elevated expression of the NLRP3 inflammasome in neutrophilic asthma, " European Respiratory Journal, vol. 43, no. 4, pp. 1067-1076, 2014.
68. H.Y. Kim, H. J. Lee, Y.-J. Chang et al., "Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity, " Nature Medicine, vol. 20, no. 1, pp. 54-61, 2014.
69. M. L. Manni, K. M. Robinson, and J. F. Alcorn, "A tale of two cytokines: IL-17 and IL-22 in asthma and infection, " Expert Review of Respiratory Medicine, vol. 8, no. 1, pp. 25-42, 2014.
70. N. Serafini, R. G. Klein Wolterink, N. Satoh-Takayama et al., "Gata3 drives development of RORyt+ group 3 innate lymphoid cells, " Journal of Experimental Medicine, vol. 211, no. 2, pp. 199- 208, 2014.
71. D. M. Durrant and D. W. Metzger, "Emerging roles of T helper subsets in the pathogenesis of asthma, " Immunological Investigations, vol. 39, no. 4-5, pp. 526-549, 2010.
72. Y.-H. Wang and M. S. Wills-Karp, "The potential role of interleukin-17 in severe asthma, " Current Allergy and Asthma Reports, vol. 11, no. 5, pp. 388-394, 2011.
73. R. Halwani, S. Al-Muhsen, and Q. Hamid, "T helper 17 cells in airway diseases from laboratory bench to bedside, " Chest, vol. 143, no. 2, pp. 494-501, 2013.
74. A. Lindén and B. Dahlén, "Interleukin-17 cytokine signalling in patients with asthma, " European Respiratory Journal, vol. 44, no. 5, pp. 1319-1331, 2014.
75. A. S. Saffar, H. Ashdown, and A. S. Gounni, "The molecular mechanisms of glucocorticoids-mediated neutrophil survival, " Current Drug Targets, vol. 12, no. 4, pp. 556-562, 2011.
76. W.W. Busse, S. Holgate, E. Kerwin et al., "Randomized, doubleblind, placebo-controlled study of brodalumab, a human anti- IL-17 receptor monoclonal antibody, in moderate to severe asthma, "The American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 11, pp. 1294-1302, 2013.
77. N. Kadowaki, "Dendritic cells: A conductor of T cell differentiation, " Allergology International, vol. 56, no. 3, pp. 193-199, 2007.
78. M. A. Berry, B.Hargadon, M. Shelley et al., "Evidence of a role of tumor necrosis factor α in refractory asthma, " The New England Journal of Medicine, vol. 354, no. 7, pp. 697-708, 2006.
79. S. E. Wenzel, P. J. Barnes, E. R. Bleecker et al., "A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma, " American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 7, pp. 549-558, 2009.
80. + T cells is associated with the phenotypes of allergic asthma, " Respirology, vol. 14, no. 2, pp. 187-194, 2009.
81. S. Provoost, T. Maes, Y.M. vanDurme et al., "DecreasedFOXP3 protein expression in patients with asthma, " Allergy, vol. 64, no. 10, pp. 1539-1546, 2009.
82. O. Palomares, M. Martín-Fontecha, R. Lauener et al., "Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-β, " Genes and Immunity, vol. 15, no. 8, pp. 511- 520, 2014.
83. C. M. Lloyd and E. M. Hessel, "Functions of T cells in asthma: more than just Tα2 cells, " Nature Reviews Immunology, vol. 10, no. 12, pp. 838-848, 2010.
84. R. H. Dougherty and J. V. Fahy, "Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype, " Clinical and Experimental Allergy, vol. 39, no. 2, pp. 193-202, 2009.
85. M. Contoli, S. D. Message, V. Laza-Stanca et al., "Role of deficient type III interferon production in asthma exacerbations, " Nature Medicine, vol. 12, no. 9, pp. 1023-1026, 2006.
86. S. Baraldo, M. Contoli, E. Bazzan et al., "Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma, " Journal of Allergy and Clinical Immunology, vol. 130, no. 6, pp. 1307-1314, 2012.